GlassScriptPhysician profile
Douglas Gilchrist Brooks
NPI 1447292305
$5,486.70
in general payments reported to CMS, 2019-2025
46 companies · $61.07 in 2025
The $61.07 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $225 · 2020: $1,074 · 2021: $1,662 · 2022: $1,044 · 2023: $561 · 2024: $859 · 2025: $61.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,481.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,481.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $720.81 | 2020-2025 | |
| Nestle Healthcare Nutrition INC. | $545.15 | 2020-2023 | |
| Lilly USA, LLC | $498.86 | 2020-2024 | Mounjaro |
| Novo Nordisk INC | $479.08 | 2020-2024 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $383.76 | 2019-2024 | Airsupra, Breztri, Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $292.39 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $201.27 | 2020-2023 | Xifaxan |
| Amgen INC. | $187.05 | 2019-2022 | |
| Noven Therapeutics, LLC | $168.07 | 2023-2024 | Xelstrym |
| Allergan, INC. | $158.24 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $135.75 | 2019-2024 | Unithroid |
| Pfizer INC. | $119.11 | 2020-2024 | |
| Janssen Pharmaceuticals, INC | $118.10 | 2021-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $114.30 | 2020-2023 | Belsomra |
| Eisai INC. | $106.58 | 2020-2021 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Brooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.